At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 8 enrolled
Drug / intervention
PF-06835919 +1 moredrug
Likely dose
PF-06835919 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MULTIPLE ORAL DOSES OF PF-06835919 IN HEALTHY ADULT JAPANESE PARTICIPANTS
In Brief
A Phase 1 clinical trial evaluating PF-06835919 and Placebo for Healthy. Completed, enrolled 8 participants across 1 site.
Detailed Summary
This is a Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of multiple oral doses of PF-06835919 in healthy adult Japanese participants. A total of approximately 8 healthy participants will be enrolled in this study. Participants will be randomized to 2 groups to receive PF-06835919 or placebo treatment with a randomization ratio of 3:1.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesBelgium
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartNov 2020
Primary CompletionMar 2021
TodayJul 2026
First PostedJun 11, 2020
Enrollment StartNov 24, 2020
Primary CompletionMar 31, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 6.1 years ago
Interventions
PF-06835919drug
PF-06835919 300 mg repeated doses
Placebodrug
Placebo repeated doses